Search results
Found 65 matches for
University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
©
Credit: University of Oxford, John Cairns
OVG professor named in New Year's Honours list
Awards & Appointments COVID-19
4 January 2024
Matthew Snape, Professor of Paediatrics and Vaccinology at the Oxford Vaccine Group (OVG) before moving to Moderna in August 2022, has been appointed Member of the Most Excellent Order of the British Empire (MBE) for services to Public Health, particularly during COVID-19 while working at the OVG.
Oxford Vaccine Group receives £7.8 million in research funding to fight pandemic and epidemic threats
COVID-19 Research
12 December 2023
Oxford Vaccine Group (OVG), which led the rapid clinical development of the Oxford vaccine in COVID-19 in the pandemic, has been awarded a total of £7,788,783 by UK Aid for research into the prevention of five dangerous diseases with epidemic or pandemic potential.
New campaign hopes to boost jab numbers
COVID-19 Methods Parents and Carers Public Engagement
8 December 2023
Experts have launched a new campaign in a bid to boost waning vaccine uptake by giving people more information about how clinical trials work. Researchers hope to alleviate hesitancy by showing with a simple animation and comic the complex way vaccines are developed.
OVG Researcher awarded prestigious NIHR Professorship
Awards & Appointments COVID-19 Department Methods Research
20 November 2023
Daniela Ferreira, Professor of Respiratory Infection and Vaccinology at the University of Oxford’s Department of Paediatrics and the Department of Clinical Sciences at the Liverpool School of Tropical Medicine has been awarded one of six prestigious Research Professorships by the National Institute of Health and Care Research (NIHR).
CEPI funding announced for development of vaccine prototype
Awards & Appointments COVID-19 Research
2 November 2023
The University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) today announced the launch of a new project to initiate early development of prototype vaccines against the Junín virus, selected as an exemplar of the Arenavirus family which is responsible for multiple deadly haemorrhagic fevers with epidemic and pandemic potential.
Oxford launches new vaccine trial to enhance design of flu & COVID-19 vaccines
COVID-19 Methods Public Engagement Research
25 October 2023
A pioneering study into human immunity is being launched today by Oxford Vaccine Group at the University of Oxford. The study, called LEGACY03, is being funded by the Medical Research Council part of UK Research and Innovation. By investigating how lymph nodes work, and how they make responses to vaccines in younger and older people, it has the potential to improve vaccine design for different age groups significantly.
First vaccine trial in older people launched for Middle East Respiratory Syndrome (MERS)
COVID-19 Methods Public Engagement Research
18 September 2023
Researchers at the University of Oxford's Pandemic Sciences Institute have launched a new clinical trial to find a vaccine to protect people against Middle East Respiratory Syndrome (MERS).
First in-human trials commence for CCHF vaccine
COVID-19 Methods Public Engagement Research
13 September 2023
A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to human volunteers for the first time. The clinical trial of the ChAdOx2 CCHF vaccine aims to confirm its safety and understand how individuals develop immunity following vaccination.
University of Oxford partners with CEPI to counter the threat of future pandemics
COVID-19 Department Public Engagement Research
30 August 2023
The University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) have entered into a strategic partnership to accelerate the development of safe, effective and globally accessible vaccines to counter the threat of future pandemics.
Director of Global Operations at OVG recognised in the King’s Birthday Honours 2023
Awards & Appointments COVID-19
22 June 2023
Dr Parvinder Aley, Director of Global Operations at the Oxford Vaccine Group, has been recognised and celebrated in the 2023 King’s Birthday Honours list. Dr Aley has been appointed an Officer of the Order of the British Empire (OBE) for services to vaccination during the COVID-19 pandemic.
Britain’s Covid research led the world – why have our clinical trials fallen off a cliff?
COVID-19
27 April 2023
Pressures on the NHS, a lack of doctors and post-Brexit delays are hampering our ability to develop cutting-edge drugs.
From running COVID-19 trials to researching respiratory diseases - Daniela Ferreira discusses her journey from Brazil to Oxford
COVID-19 Research
7 December 2022
Daniela Ferreira, Professor of Mucosal Immunity and Infection at the Oxford Vaccine Group, Department of Paediatrics, has so much enthusiasm for her work on respiratory infections and vaccinology, you would be very hard-pressed not to want her to succeed
It’s not just Covid: the triple threat that could overwhelm the NHS this winter - Andrew Pollard
COVID-19
13 September 2022
A severe flu outbreak or new coronavirus variant could prove catastrophic for a health service already on its knees
Novel all-in-one vaccine developed to tackle future coronavirus threats
COVID-19
6 July 2022
Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.
Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds
COVID-19
26 May 2022
Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.
Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study
COVID-19
16 May 2022
COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.
Oxford to work with Brazil to establish clinical research hub
COVID-19 Research
8 November 2021
The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.
One billion doses: A moment to celebrate but not a time to be complacent
COVID-19
30 July 2021
Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group and Professor of Paediatric Infection and Immunity, takes a moment to reflect on one billion doses of the Oxford coronavirus vaccine released worldwide.
Severe disease, not mild infection, makes a pandemic – vaccines still offer our best hope
COVID-19
30 July 2021
If the current high levels of protection against severe disease are sustained, the global public health emergency will be curtailed by the ongoing vaccine rollout - writes Andrew Pollard for The Independent.
Oxford vaccine reaches one billion doses released
COVID-19
29 July 2021
The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.